About the Program:
Program Overview
ARV Therapies and Therapeutic Strategies program is a comprehensive, expert review of the 15th European AIDS Conference (EACS 2015). This program consists of five components: (1) CME Internet Symposium: EACS 2015 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) CME Internet Symposium: Brazilian Perspective on EACS 2015: a 1-hour Internet symposium featuring Brazil-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in Brazil; (3) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium; (4) Rapid-Fire Review of EACS 2015: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (5) From Conference to Clinic: Reviewing and Applying Data From EACS 2015: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.
The Comprehensive Expert Review and Discussion of Key Presentations part of the program will feature HIV experts reviewing and discussing the most important studies on antiretroviral therapy presented at EACS 2015. This review and discussion will provide a comprehensive overview of each of the posters and presentations selected. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from EACS and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EACS 2015 and it is not sanctioned by the organizers of EACS 2015.
Back to Top
Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
Back to Top
Learning Objectives
After completing this activity, the participant should be better able to:
-
Use in a clinical setting findings from key new studies on HIV/AIDS diagnosis, management and treatment presented at EACS 2015
-
Employ the current treatment paradigms for HIV/AIDS, including those supported by studies and data presented at EACS 2015 to improve patient care
-
Discuss with patients and colleagues the studies and data on newer therapies for HIV/AIDS presented at EACS 2015 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS
Release Date: November 2, 2015
Expiration Date: November 3, 2016
Estimated time to complete each Poster/Presentation: 15-30 minutes
Media: Internet
Back to Top
Faculty
José Arribas, MD
Research Director
(AIDS and Infectious Diseases)
Hospital de La Paz
Madrid, Spain
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
Jürgen Rockstroh, MD
Professor, University of Bonn
Bonn, Germany
Back to Top
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Back to Top
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.
Back to Top
Disclosure of Conflicts of Interest
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Dr. Jose Arribas:
- Consulting Fees: Gilead; Janssen; Vertex
- Fees for Non-CME Services: Gilead; BMS; Merck; Janssen; Vertex
- Contracted Research: Gilead; GSK; Janssen; Vertex; Salix; Sangamo
Dr. Ian Frank:
- Consulting Fees: Abbott; Aileron; BMS; Gilead; GSK; Merck; Tibotec
- Other - Grant Support: BMS; Gilead; Merck; GSK; Tibotec
Dr. Graeme Moyle:
- Consulting Fees: Abbott; Gilead
- Contracted Research: BMS; Abbott
Dr. Juergen Rockstroh:
- Consulting Fees: Gilead; Janssen; Bristol-Myers Squibb
- Contacted Research: Bristol-Myers Squibb; Pfizer; Gilead; VIRxSyS; GSK
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Gilead Sciences Medical Affairs. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Gilead Sciences Medical Affairs. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Poster/Presentation Listing
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Back to Top
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
|